PharmaCorp Rx

What PharmaCorp Rx does

PharmaCorp Rx is a Canadian pharmacy acquisition and ownership platform that buys and operates independent community pharmacies, primarily under the PharmaChoice Canada banner. The company's core product is a pharmacy succession and acquisition service: it provides capital, operational integration, and co-ownership structures to retiring independent pharmacists seeking exit options that preserve legacy, retain staff, and maintain community care. A secondary product, the Pharmacist Equity Partnership Program, enables next-generation pharmacists to acquire meaningful equity stakes in established pharmacies alongside PharmaCorp. PharmaCorp is publicly listed on the TSX Venture Exchange (symbol PCRX), was originally incorporated as Proton Capital Corp. in 2021, and completed its Qualifying Transaction in June 2024 through the acquisition of 75% of Saskatoon Family Pharmacy Ltd. and a strategic alliance with PharmaChoice Canada.

The company generates revenue by operating acquired pharmacies through prescription drug sales and front-store retail. Acquisition strategy is channel-driven: a Strategic Alliance Agreement with PharmaChoice Canada provides right-of-first-refusal access to the 1,050+ member banner (Canada's 3rd largest pharmacy banner), and a Retail Collaboration Agreement with McKesson Canada extends the pipeline to Guardian, I.D.A., and Remedy'sRx banner pharmacies. Acquisitions range from approximately C$300K for prescription files to over C$15M for full pharmacy businesses including real estate. PharmaCorp operates across Western Canada, Eastern Canada, Atlantic Canada, and Ontario, where a pre-1954 charter company acquisition enables legal ownership under Ontario's restrictive Drug and Pharmacies Regulations Act. The platform has no disclosed proprietary technology; its value proposition is built on banner-affiliated distribution, capital access through public markets and a C$20.5M CIBC credit facility, and leadership experience drawn from PharmaChoice Canada and Rexall Drugs.

FY2025 revenue was C$20.9M versus C$5.8M in 2024, with same-store sales up 6% and prescription sales up 3.8%. As of mid-2026, PharmaCorp had announced acquisitions expected to take the operating footprint to 14-15 locations, with C$24.2M (eight Eastern Canada pharmacies) and C$8.2M (Morrisburg, Ontario) deals in definitive or pending status, and a C$100M base shelf prospectus providing funding optionality for further M&A.

Name

PharmaCorp Rx

Legal name

PharmaCorp Rx Inc.

Website

https://pharmacorprx.ca

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmaCorp Rx is a Canadian pharmacy acquisition platform that buys and operates independent community pharmacies under the PharmaChoice Canada banner, providing succession, capital, and co-ownership solutions to retiring and next-generation pharmacists across Western, Eastern, Atlantic, and Ontario Canada.

Ownership category

akta.pro rank

Product category

Community Pharmacy Operations

NAICS

Pharmacies and Drug Retailers (456110)

SIC

Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Retail & Community Pharmacies (Chain/Independent) (HLAFALAA)

akta.pro secondary industry

Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI)

Keywords

• Pharmacy acquisition services
• Pharmacy succession planning
• Community pharmacy operations
• Pharmacy ownership transitions
• Pharmacy banner partnerships

Headquarters

HQ city

Saskatoon

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmacy Operations: PharmaCorp Rx generates revenue through operating acquired pharmacies under the PharmaChoice Canada banner. Revenue comes from prescription drug sales and front-store retail sales. Same-store sales grew 6% and prescription sales rose 3.8% in fiscal 2025. The company achieves growth through acquisitions and operational improvements including centralized systems and procurement leverage.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

PharmaCorp Rx is a Canadian pharmacy acquisition and ownership platform that acquires independent community pharmacies from retiring owners and continues operating them under the PharmaChoice Canada banner. The company provides succession planning, capital, and operational support to selling pharmacists while offering equity co-ownership opportunities to next-generation pharmacists. Revenue is generated primarily through prescription drug sales and front-store retail sales at owned pharmacy locations, with FY2025 revenue of $20.9M.

Product overview

PharmaCorp Rx operates as a single unified platform for pharmacy succession and acquisition services in Canada. The core offering is their Pharmacy Succession and Acquisition Platform, which provides end-to-end support for independent pharmacy owners looking to sell or transition their businesses. A key component is the Pharmacist Equity Partnership Program, which enables co-ownership structures where pharmacists can partner with PharmaCorp to acquire equity in pharmacies. The company builds and operates pharmacies under the PharmaChoice Canada banner through its strategic alliance, and has also established a Retail Collaboration Agreement with McKesson Canada for Guardian, I.D.A., and Remedy'sRx banner pharmacies.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmacy Succession and Acquisition Platform

Quantifiable outcome

• Same-store sales grew 6% in fiscal 2025
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered major and core.

• LodeRock Advisors Inc.majorGTM or Marketing Partner · 13 April 202612-month investor relations services agreement effective April 2026. LodeRock develops and executes investor relations strategy, manages investor communications, and provides market intelligence. Monthly fee of $10,000 for first six months, increasing to $12,500 thereafter with 2.5% annual escalation.
• McKesson Canada CorporationcoreStrategic or Co-development Partner · 25 February 2026Retail Collaboration Agreement positions PharmaCorp as a continuity platform for independent pharmacies operating under McKesson Canada's Guardian, I.D.A., and Remedy'sRx banners. The partnership supports succession planning for McKesson banner pharmacy owners while enabling next-generation pharmacists to acquire equity through PharmaCorp's co-ownership program. The agreement provides a preferred acquisition framework for McKesson banner pharmacies considering ownership transitions.
• PharmaChoice Canada Inc.coreStrategic or Co-development Partner · 31 August 2023Strategic alliance agreement executed in August 2023 provides PharmaCorp with preferential acquisition rights to PharmaChoice bannered pharmacies through a right-of-first-refusal agreement. The partnership includes license, ROFR, and master membership agreements. PharmaChoice is Canada's 3rd largest pharmacy banner with 1,050+ member stores. The alliance gives PharmaChoice members a viable exit strategy while providing PharmaCorp with a stable pipeline of acquisitions.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Whole Health Pharmacy Partners: Canadian pharmacy partnership platform offering co-ownership and succession solutions to independent pharmacists. Operates a banner model with shared services, directly comparable to PharmaCorp's acquisition and equity partnership approach.
• Pharmasave Pacific: Canadian cooperative-style pharmacy banner with 1,000+ member stores. Operates a similar banner-affiliated model for independent pharmacies and is one of the primary alternatives for Canadian pharmacy owners considering succession or affiliation.
• The Medicine Shoppe Canada: Canadian franchise pharmacy model focused on independent pharmacy owners. Provides branding, procurement, and operational support under a partnership structure analogous to PharmaCorp's banner-aligned acquisition approach.
• Guardian Pharmacy Group: Banner network of independent Canadian pharmacies distributed by McKesson Canada. Shares PharmaCorp's target customer (independent owners seeking succession) and operates a competing banner-affiliated model.

Broad incumbents

• Loblaw Companies (Shoppers Drug Mart): Canada's largest pharmacy operator through Shoppers Drug Mart with 1,800+ locations. Represents the dominant incumbent in retail pharmacy and an indirect competitor for succession candidates, given its scale advantages.
• Metro Inc. (Jean Coutu): Owns the Jean Coutu pharmacy banner in Quebec and Ontario with hundreds of franchised locations. A broad incumbent in Canadian retail pharmacy and a competing destination for independent pharmacy succession arrangements.
• Rexall Pharmacy Group: National chain pharmacy operator owned by McKesson Canada with hundreds of corporate stores. Operates as a broad incumbent in the same retail pharmacy space where PharmaCorp's banner-aligned stores compete.
• McKesson Canada: Major pharmaceutical distributor and pharmacy operator in Canada, parent of Guardian/IDA/Remedy'sRx banners. Counterparty to PharmaCorp's Retail Collaboration Agreement and a broad incumbent in retail pharmacy distribution.

Others

• PharmaChoice Canada: Canada's 3rd largest pharmacy banner with 1,050+ member stores and PharmaCorp's primary strategic partner. Functions as both pipeline source and banner affiliation; an ecosystem participant rather than direct competitor.

Emerging players

• The Pharma Network (PPN): Canadian pharmacy network focused on independent pharmacy support and group purchasing. A smaller emerging player in the same pharmacy partnership/affiliation category that PharmaCorp operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmacorprx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaCorp Rx